Carbetocin Or Oxytocin To Prevent Postpartum Haemorrhage Due To Uterine Aony In Cases Of Elective Caesarean Section
DOI:
https://doi.org/10.14738/assrj.77.8666Abstract
Background: Despite the technological advancement made in the past few decades, postpartum haemorrhage (PPH) remains one of the principal causes of maternal deaths in developing nations. The administration of uterotonic drugs widely prevents the PPH; therefore, it is the main point of active management. Among uterotonics, oxytocin has proven to be very effective in reducing the incidence of PPH. One prophylactic drug which has been introduced in recent times is carbetocin, a synthetic long-acting oxytocin analogue. It has a longer half life of 41 min, allowing it to stimulate a prolonged uterine response of up to an hour after a single intravenous dose, obviating the need for infusion.
Methods: A total of 120 pregnant women divided into two groups; Group I (Carbetocin group) included 60 women who received carbetocin and delivered by caesarean section (CS), Group II (Oxytocin group) included 60 women who received oxytocin and delivered by caesarean section (CS).
Results: Our result showed that, there was a statistically significant difference for the prevention of atonic postpartum hemorrhage between the two groups (p<0.01), for carbetocin group. There was also a statistically significant difference between the two groups (p < 0.01), according to need to additional procedures, such as need to modified B-lynch sutures and need to bilateral uterine arteries ligation for carbetocin group.
Conclusion: We concluded that carbetocin was a better alternative to traditional oxytocin in the prevention of PPH after elective caesarean section.
References
Say L, Chou D, Gemmill A, Tuncalp O, Moller Ab, Daniels J, et al. (2014): Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health; 2(6): e323e33. [2] Wang CY, Chen YC,L.
World Health Orgnization (2012): WHO recommendations for the prevention and treatment of postpartum haemorrhage. WHO Guidelines Approved by the Guidelines Review Committee, Geneva.
Westhof G, Cotter AM, Tolosa JE (2013): Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev.
Rozenberg P, Quibel T, Ghout I, Salomon L, Bussiere L, Goffinet F (2016): Active management of the third stage of labor with routine oxytocin and misoprostol for the prevention of postpartum hemorrhage: a randomized controlled trial. Am J Obstet Gynecol.; 212 (Suppl. 1 : S 18).
Boucher M, Horbay GL, Griffin P, Deschamps Y, Desjardins C, Schulz M, et al. (1998): Double-blind randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uterine tone of patients undergoing caesarean section. J Perinatol. 18 : 202 – 207. [Pubmed][Google Scholar].
Ferring Pharmaceuticals. Product monograph: Pabal@ (Carbetocin 100 micrograms/mL solution for injection). May 2015.
Su LL, Shong YS, Samuel M (2012): Carbetocin for preventing postpartum haemorrhage. Cochranen Database Syst Rev.; 2 :
CD005457. [PubMed][Google Scholar].
Magann EF, Evans S, Chauhan SP, Lanneau G, Fisk AD,
Morrison JC (2005). The length of the third stage of labor and the risk of postpartum hemorrhage Obstetrics & Gynecology. Feb 1; 105
(2): 290 – 3. URL: http://dx.doi.org/10.14738/assrj.77.8666 744
Gülmezoglu AM, Lumbiganon P, Landoulsi S, Widmer M, AbdelAleem H, Festin M, Carroli G, Qureshi Z, Souza JP, Bergel E, Piaggio G (2012). Active management of the third stage of labour with and without controlled cord traction: a randomized, controlled, non-inferiority trial. The Lancet. May 5; 379 (9827): 1721 – 7.
Widmer M, Piaggio G, Nguyen TM, Osoti A, Owa OO, Misra S, Coomarasamy A, Abdel-Aleem H, Mallapur AA, Qureshi Z, Lumbiganon P (2018). Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine. Aug 23; 379 (8): 743 – 52.
Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER, Farine D, Schulz ML, Horbay GL, Griffin P, Wassenaar W (1999). Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. American Journal of obstetrics and gynecology. Mar 1; 180 (3): 670 – 6.
Boucher M, Nimrod CA, Tawagi GF, Meeker TA, White RE, varin J (2004). Comparison of carbetocin and oxytocin for the prevention of postpartum hemorrhage following vaginal delivery: A double-blind randomized trial. Journal of Obsetrics and Gynaecology Canada. May 1; 26 (5): 481-8.
Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, Hunt LP, Draycott T (2010). Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: The results of a doubleblind randomized trial. BJOG: An international journal of Obstetrics & Gynecology. Jul; 117 (8): 929 – 36.
Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B, Centonze C, Bompiani A, Malandrenis I, Cirese A, Valensise H (2013). Carbetocin Versus oxytocin in caesarean section with high risk of post-partum haemorrhage. Journal of prenatal medicine. Jan; 7 (1): 12.
Maged AM, Hassan AM, Shehata NA (2016). Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. The journal of Maternal-Fetal & Neonatal Medicine. Feb 16; 29 (4): 532 – 6.
Amornpetchakul P, Lertbunnaphong T, Boriboonhiransarn D, Leetheeragul J, Sirisomboon R, Jiraprasertwong R (2018). Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in highrisk singleton pregnancies: A triple-blind randomized controlled trial. Archives of gynecology and obstetrics. Aug 1; 298 (2): 319 – 27.
Reyes OA, Gonzalez GM (2011). Carbetocin versus oxytocin for prevention of postpartum hemorrhage in patients with severe preeclampsia: a double-blind randomized controlled trial. Journal of obstetrics and Gynaecology Canad. Nov 1; 33 (11): 1099 – 104.
Samimi M, Imani-Harsini A, Abedzadeh-Kalahroudi M. (2013). Carbetocin vs. Syntometrine in prevention of postpartum hemorrhage: a double blind randomized control trial Iranian Red Crescent Medical Journal. Sep; 15 (9): 817.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Mohamed S. A. Emarah
This work is licensed under a Creative Commons Attribution 4.0 International License.
